AP
SRPT icon

Appleton Partners’s Sarepta Therapeutics SRPT Stock Holding History

Appleton Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,080
Closed -$203K – 267
2020
Q1 		$203K Hold
2,080
– – 0.03% 253
2019
Q4 		$268K Buy
+2,080
New +$210K 0.03% 260
2019
Q3 		– Sell
-2,080
Closed -$316K – 285
2019
Q2 		$316K Hold
2,080
– – 0.04% 226
2019
Q1 		$248K Hold
2,080
– – 0.03% 241
2018
Q4 		$227K Hold
2,080
– – 0.03% 240
2018
Q3 		$336K Hold
2,080
– – 0.04% 215
2018
Q2 		$275K Buy
+2,080
New +$196K 0.04% 229

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Appleton Partners's SRPT Position: Q2 2020 in Review

Appleton Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 2,080 shares — an estimated $203K sold.

Appleton Partners first reported a position in SRPT in Q2 2018 and held it in 7 quarters. The position peaked at $336K in Q3 2018. 408 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

  • Appleton Partners reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Appleton Partners sold 2,080 Sarepta Therapeutics shares in Q2 2020, an estimated $203K.
  • Appleton Partners first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 7 quarters.
  • Appleton Partners's Sarepta Therapeutics position peaked at $336K in Q3 2018.
  • 408 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Appleton Partners's 13F filing for Q2 2020, filed 14 Aug 2020.